Abstract

Targeting ferritin via autophagy (ferritinophagy) to induce ferroptosis, an iron- and reactive oxygen species (ROS)-dependent cell death, provides novel strategies for cancer therapy. Using a ferroptosis-specific inhibitor and iron chelator, the vulnerability of triple-negative breast cancer (TNBC) MDA-MB-231 cells to ferroptosis was identified and compared to that of luminal A MCF-7 cells. Saponin formosanin C (FC) was revealed as a potent ferroptosis inducer characterized by superior induction in cytosolic and lipid ROS formation as well as GPX4 depletion in MDA-MB-231 cells. The FC-induced ferroptosis was paralleled by downregulation of ferroportin and xCT expressions. Immunoprecipitation and electron microscopy demonstrated the involvement of ferritinophagy in FC-treated MDA-MB-231 cells. The association of FC with ferroptosis was strengthened by the results that observed an enriched pathway with differentially expressed genes from FC-treated cells. FC sensitized cisplatin-induced ferroptosis in MDA-MB-231 cells. Through integrated analysis of differentially expressed genes and pathways using the METABRIC patients’ database, we confirmed that autophagy and ferroptosis were discrepant between TNBC and luminal A and that TNBC was hypersensitive to ferroptosis. Our data suggest a therapeutic strategy by ferroptosis against TNBC, an aggressive subtype with a poor prognosis.

Highlights

  • According to the World Health Organization, breast cancer is the most prevalent cancer and ranked 5th among cancer-related deaths in 2020

  • To determine the sensitivity of these two subtypes to ferroptosis, the triple-negative breast cancer (TNBC) MDA-MB-231 and the luminal A MCF-7 cells were treated with the ferroptosis inducer, erastin or RSL3

  • We found that RSL3 and erastin were efficacious in the suppression of cell growth, and the trend was more pronounced in MDA-MB-231 than in MCF-7 cells (Figure 1A)

Read more

Summary

Introduction

According to the World Health Organization, breast cancer is the most prevalent cancer and ranked 5th among cancer-related deaths in 2020. In light of its high heterogeneity, breast cancer is clinically divided into three main subtypes based on the expression of hormone receptors, namely estrogen receptor (ER) and progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): luminal, HER2-positive, and triple-negative breast cancer (TNBC). The luminal subtype expresses ER, PR, or both, and is further subdivided into luminal A (HER2-negative) and B (HER2-positive) groups [1]. A, luminal B, HER2-positive, and TNBC cases account for up to 70%, 10–20%, 5–15%, and. ~15% of all breast cancer patients, respectively [2,3]. Compared to luminal A, luminal B has a worse prognosis [4]. Drug targeting of HER2 is known to substantially improve the prognosis of HER2-positive breast cancer [5].

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.